Format

Send to

Choose Destination
ERJ Open Res. 2019 May 10;5(2). pii: 00194-2018. doi: 10.1183/23120541.00194-2018. eCollection 2019 Apr.

From the pathophysiology of the human lung alveolus to epigenetic editing: Congress 2018 highlights from ERS Assembly 3 "Basic and Translational Science."

Author information

1
University College London, Division of Medicine, London, UK.
2
These contributed equally to this work.
3
H12O-CNIO Lung Cancer Clinical Research Unit, Research Institute Hospital 12 Octubre - Spanish National Cancer Research Centre (CNIO), and Biomedical Research Networking Centre Consortium of Cancer (CIBERONC), Madrid, Spain.
4
Comprehensive Pneumology Center, Ludwig-Maximilians University (LMU), University Hospital Grosshadern, and Helmholtz Zentrum München; Member of the German Center for Lung Research (DZL), Munich, Germany.
5
University College Dublin, St Vincent's University Hospital, Elm Park, Dublin, Ireland.
6
University of Groningen, University Medical Center Groningen, Depts of Pathology and Medical Biology and Pulmonology, GRIAC Research Institute, Groningen, The Netherlands.
7
Dept of Pharmacology and Toxicology, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
8
Lung Biology Group, Dept of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland.
9
Dept of Pulmonology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
10
Early Life Origins of Chronic Lung Disease, Research Center Borstel, Leibniz Lung Center, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Borstel, Germany.

Abstract

The European Respiratory Society (ERS) International Congress is the largest respiratory congress and brings together leading experts in all fields of respiratory medicine and research. ERS Assembly 3 shapes the basic and translational science aspects of this congress, aiming to combine cutting-edge novel developments in basic research with novel clinical findings. In this article, we summarise a selection of the scientific highlights from the perspective of the three groups within Assembly 3. In particular, we discuss new insights into the pathophysiology of the human alveolus, novel tools in organoid development and (epi)genome editing, as well as insights from the presented abstracts on novel therapeutic targets being identified for idiopathic pulmonary fibrosis.

Conflict of interest statement

Conflict of interest: M.Z. Nikolić has nothing to disclose. Conflict of interest: E.M. Garrido-Martin is a member of Bristol Myers Squibb's scientific advisory board, outside the submitted work. Conflict of interest: F.R. Greiffo has nothing to disclose. Conflict of interest: A. Fabre has nothing to disclose. Conflict of interest: I.H. Heijink has nothing to disclose. Conflict of interest: A. Boots has nothing to disclose. Conflict of interest: C.M. Greene has nothing to disclose. Conflict of interest: P.S. Hiemstra reports research grant to his department from Boehringer Ingelheim and Galapagos, outside the submitted work. Conflict of interest: S. Bartel reports grants and personal fees from Bencard Allergie GmbH, outside the submitted work.

Publication type

Publication type

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center